C.E.M. Griffiths

70.9k total citations · 13 hit papers
762 papers, 45.1k citations indexed

About

C.E.M. Griffiths is a scholar working on Immunology, Dermatology and Molecular Biology. According to data from OpenAlex, C.E.M. Griffiths has authored 762 papers receiving a total of 45.1k indexed citations (citations by other indexed papers that have themselves been cited), including 444 papers in Immunology, 381 papers in Dermatology and 90 papers in Molecular Biology. Recurrent topics in C.E.M. Griffiths's work include Psoriasis: Treatment and Pathogenesis (388 papers), Dermatology and Skin Diseases (241 papers) and Skin Protection and Aging (95 papers). C.E.M. Griffiths is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (388 papers), Dermatology and Skin Diseases (241 papers) and Skin Protection and Aging (95 papers). C.E.M. Griffiths collaborates with scholars based in United Kingdom, United States and Germany. C.E.M. Griffiths's co-authors include Juliet N. Barker, Darren M. Ashcroft, Rosa Parisi, Helen L. Richards, Dónal G. Fortune, Deborah Symmons, Kim Papp, John J. Voorhees, Chris J. Main and Kristian Reich and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

C.E.M. Griffiths

735 papers receiving 43.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2012 1.9k citations Rosa Parisi, C.E.M. Griffiths et al. Journal of Investigative Dermatology profile →
Pathogenesis and clinical features of psoriasis

2007 1.6k citations C.E.M. Griffiths, Juliet N. Barker profile →
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

2014 1.5k citations Mark Lebwohl, Kristian Reich et al. profile →
Psoriasis

2021 1.4k citations C.E.M. Griffiths, Juliet N. Barker et al. profile →
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

2005 838 citations Kristian Reich, Kim Papp et al. profile →
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study

2020 730 citations Rosa Parisi, Evangelos Kontopantelis et al. profile →
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

2015 658 citations C.E.M. Griffiths, Kristian Reich et al. profile →
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

2010 644 citations C.E.M. Griffiths et al. profile →
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

2017 637 citations Andrew Blauvelt, Kim Papp et al. profile →
Keratinocytes as initiators of inflammation

1991 637 citations Juliet N. Barker, C.E.M. Griffiths et al. profile →
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

2005 557 citations Kim Papp, C.E.M. Griffiths et al. British Journal of Dermatology profile →
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

2015 483 citations Kim Papp, Kristian Reich et al. profile →
Psoriasis Prevalence in Adults in the United States

2021 278 citations C.E.M. Griffiths et al. profile →

Peers

Countries citing papers authored by C.E.M. Griffiths

Since Specialization

Citations

This map shows the geographic impact of C.E.M. Griffiths's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.E.M. Griffiths with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.E.M. Griffiths more than expected).

Fields of papers citing papers by C.E.M. Griffiths

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.E.M. Griffiths. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.E.M. Griffiths. The network helps show where C.E.M. Griffiths may publish in the future.

Co-authorship network of co-authors of C.E.M. Griffiths

This figure shows the co-authorship network connecting the top 25 collaborators of C.E.M. Griffiths. A scholar is included among the top collaborators of C.E.M. Griffiths based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.E.M. Griffiths. C.E.M. Griffiths is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estimating the burden of vitiligo: a systematic review and modelling study 2024 ·The Lancet Public Health ·(unknown), Solam Lee, Hyun Jeong Ju, Rosa Parisi, (unknown), (unknown), (unknown), Viktoria Eleftheriadou, Iltefat Hamzavi, C.E.M. Griffiths, Darren M. Ashcroft, Venkataram Mysore, Somesh Gupta, Davinder Parsad, Henry W. Lim, Jung Min Bae, Khaled Ezzedine	36
2	Retinoids in the treatment of photoageing: A histological study of topical retinoid efficacy in black skin 2024 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), (unknown), (unknown), Anna L. Chien, Sewon Kang, (unknown), Mike Bell, C.E.M. Griffiths, Rachel Watson, A.K. Langton	4
3	Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials 2023 ·SKIN The Journal of Cutaneous Medicine ·Linda Stein Gold, C.E.M. Griffiths, Anna M. Tallman, Philip Marshall Brown, Mark Lebwohl	1
4	Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in Psoriasis 2023 ·Cells ·Peter West, Chiara Tontini, (unknown), (unknown), (unknown), Rajia Bahri, Richard B. Warren, C.E.M. Griffiths, Adam Stevens, Silvia Bulfone‐Paus	6
5	Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) 2023 ·British Journal of Dermatology ·(unknown), Anthony Bewley, Catherine Smith, Teena Mackenzie, C.E.M. Griffiths, Mark Lunt, Richard B. Warren, Zenas Z N Yiu	3
6	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study 2022 ·SHILAP Revista de lepidopterología ·Suzie Cro, Victoria Cornelius, Francesca Capon, Juliet N. Barker, A. David Burden, C.E.M. Griffiths, Helen J. Lachmann, Helen McAteer, Prakash A. Patel, Andrew Pink, Nick J. Reynolds, Richard B. Warren, Catherine Smith	1
7	Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK) 2022 ·Thorax ·(unknown), Paul Pfeffer, Giulia Vivaldi, Hayley Holt, Mohammad Talaei, David A. Jolliffe, Gwyneth A. Davies, Ronan A Lyons, C.E.M. Griffiths, Frank Kee, Aziz Sheikh, Seif O. Shaheen, Adrian R. Martineau	13
8	Peptide location fingerprinting reveals modification‐associated biomarker candidates of ageing in human tissue proteomes 2021 ·Aging Cell ·Matiss Ozols, Alexander Eckersley, Kieran T. Mellody, Venkatesh Mallikarjun, Stacey Warwood, ronan.ocualain not provided, David Knight, Rachel Watson, C.E.M. Griffiths, Joe Swift, Michael J. Sherratt	19
9	Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study 2021 ·PLoS ONE ·(unknown), Rosa Parisi, Martin K. Rutter, Evangelos Kontopantelis, C.E.M. Griffiths, Darren M. Ashcroft, (unknown)	4
10	‘Mind the gap’: what patients and clinicians believe is ‘unknown’ about psoriasis 2020 ·British Journal of Dermatology ·Rabiya Majeed‐Ariss, (unknown), Helen McAteer, C.E.M. Griffiths, Helen Young	0
11	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) 2020 ·British Journal of Dermatology ·Zenas Z N Yiu, K.J. Mason, Philip Hampton, Nick J. Reynolds, Catherine Smith, Mark Lunt, C.E.M. Griffiths, Richard B. Warren, (unknown)	74
12	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis 2019 ·British Journal of Dermatology ·Zenas Z N Yiu, K.J. Mason, Juliet N. Barker, Philip Hampton, Kathleen McElhone, Catherine Smith, Richard B. Warren, C.E.M. Griffiths, Mark Lunt, A. David Burden, (unknown)	16
13	Genetic interaction between placental growth factor and vascular endothelial growth factor A in psoriasis 2019 ·Clinical and Experimental Dermatology ·Helen Young, Ian Kamaly-Asl, Philip Laws, P. Pemberton, C.E.M. Griffiths	6
14	Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology 2017 ·Journal of Investigative Dermatology ·Amy Foulkes, David Watson, C.E.M. Griffiths, Richard B. Warren, Wolfgang Huber, Michael R. Barnes	12
15	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) 2017 ·British Journal of Dermatology ·Kim Papp, C. Leonardi, Andrew Blauvelt, Kristian Reich, (unknown), Mamitaro Ohtsuki, C. Paul, Susan Ball, Gregory S. Cameron, J. Erickson, (unknown), Lotus Mallbris, C.E.M. Griffiths	77
16	Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells 2015 ·Molecular BioSystems ·Katherine A. Hollywood, Catherine Winder, Warwick B. Dunn, Yun Xu, David Broadhurst, C.E.M. Griffiths, Royston Goodacre	23
17	Acne conglobata and adalimumab: use of tumour necrosis factor-α antagonists in treatment-resistant acne conglobata, and review of the literature 2014 ·Clinical and Experimental Dermatology ·Zenas Z N Yiu, Vishal Madan, C.E.M. Griffiths	32
18	So you want to be … a dermatologist 2009 ·British Journal of Hospital Medicine ·Stephanie Ogden, C.E.M. Griffiths	3
19	Psoriasis: background and clinical features 2007 ·Research Explorer (The University of Manchester) ·C.E.M. Griffiths, J E Barker	13
20	Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in Psoriasis. 1996 ·Acta Dermato Venereologica ·C.E.M. Griffiths, M. J. Boffa, W M Gallatin, Stéphan Martin	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact